PD1/PD-L1 X-适体的筛选。
Selection of PD1/PD-L1 X-Aptamers.
机构信息
Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX, 77030, USA.
AM Biotechnologies, LLC, 12521 Gulf Freeway, Houston, TX, 77034, USA.
出版信息
Biochimie. 2018 Feb;145:125-130. doi: 10.1016/j.biochi.2017.09.006. Epub 2017 Sep 11.
Abstract
Specific, chemically modified aptamers (X-Aptamers) were identified against two immune checkpoint proteins, recombinant Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1). Selections were performed using a bead-based X-Aptamer (XA) library containing several different amino acid functional groups attached to dU at the 5-position. The binding affinities and specificities of the selected XA-PD1 and XA-PDL1 were validated by hPD-1 and hPD-L1 expression cells, as well as by binding to human pancreatic ductal adenocarcinoma tissue. The selected PD1 and PDL1 XAs can mimic antibody functions in in vitro assays.
摘要
针对两种免疫检查点蛋白，即重组程序性死亡受体 1（PD-1）和程序性死亡配体 1（PD-L1），鉴定了特定的、化学修饰的适体（X-适体）。选择是使用一种基于珠子的 X-适体（XA）文库进行的，该文库包含了几种不同的氨基酸官能团，连接在 dU 的 5 位上。所选 XA-PD1 和 XA-PDL1 的结合亲和力和特异性通过 hPD-1 和 hPD-L1 表达细胞以及与人胰腺导管腺癌组织的结合进行了验证。所选的 PD1 和 PDL1 XAs 可以在体外实验中模拟抗体的功能。
相似文献
1
Selection of PD1/PD-L1 X-Aptamers.
Biochimie. 2018 Feb;145:125-130. doi: 10.1016/j.biochi.2017.09.006. Epub 2017 Sep 11.
2
Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy.
Chem Commun (Camb). 2020 Dec 4;56(93):14653-14656. doi: 10.1039/d0cc06032a. Epub 2020 Nov 6.
3
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3.
4
Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
J Mater Chem B. 2021 Jan 28;9(3):746-756. doi: 10.1039/d0tb01668c.
5
X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
Biochimie. 2021 Feb;181:25-33. doi: 10.1016/j.biochi.2020.11.018. Epub 2020 Nov 23.
6
Aptamer-assisted phage display: enhancing checkpoint inhibition with a peptide and an aptamer targeting distinct sites on a single PD-L1 protein.
Chem Commun (Camb). 2024 Jul 18;60(59):7570-7573. doi: 10.1039/d4cc02132k.
7
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
J Hematol Oncol. 2020 May 19;13(1):55. doi: 10.1186/s13045-020-00891-5.
8
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
BMC Cancer. 2017 Sep 5;17(1):618. doi: 10.1186/s12885-017-3634-5.
9
Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
Immunol Invest. 2020 Jul;49(5):535-554. doi: 10.1080/08820139.2020.1744639. Epub 2020 May 19.
10
An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
J Recept Signal Transduct Res. 2018 Feb;38(1):31-36. doi: 10.1080/10799893.2017.1414843. Epub 2017 Dec 18.
引用本文的文献
1
Aptamer based immunotherapy: a potential solid tumor therapeutic.
Front Immunol. 2025 Feb 17;16:1536569. doi: 10.3389/fimmu.2025.1536569. eCollection 2025.
2
Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging.
Sci Rep. 2024 Nov 19;14(1):28652. doi: 10.1038/s41598-024-74891-7.
3
bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
Int J Mol Sci. 2023 Feb 9;24(4):3525. doi: 10.3390/ijms24043525.
4
Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future.
Front Cell Dev Biol. 2022 Nov 1;10:1048148. doi: 10.3389/fcell.2022.1048148. eCollection 2022.
5
Cancer immunomodulation using bispecific aptamers.
Mol Ther Nucleic Acids. 2022 Jan 10;27:894-915. doi: 10.1016/j.omtn.2022.01.008. eCollection 2022 Mar 8.
6
Synthesis and characterization of novel ssDNA X-aptamers targeting Growth Hormone Releasing Hormone (GHRH).
PLoS One. 2022 Jan 21;17(1):e0260144. doi: 10.1371/journal.pone.0260144. eCollection 2022.
7
The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.
Front Immunol. 2021 Feb 25;12:602330. doi: 10.3389/fimmu.2021.602330. eCollection 2021.
8
X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
Biochimie. 2021 Feb;181:25-33. doi: 10.1016/j.biochi.2020.11.018. Epub 2020 Nov 23.
9
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Dis Markers. 2020 Sep 21;2020:7656031. doi: 10.1155/2020/7656031. eCollection 2020.
10
Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.
Radiat Oncol. 2020 Aug 5;15(1):189. doi: 10.1186/s13014-020-01624-1.
本文引用的文献
1
Ipilimumab-Based
Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab.
Clin J Oncol Nurs. 2017 Aug 1;21(4 Suppl):30-41. doi: 10.1188/17.CJON.S4.30-41.
2
X-Aptamer Selection and Validation.
Methods Mol Biol. 2017;1632:151-174. doi: 10.1007/978-1-4939-7138-1_10.
3
Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.
Eur J Cancer. 2017 Sep;83:71-79. doi: 10.1016/j.ejca.2017.06.021. Epub 2017 Jul 15.
4
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
5
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
6
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
J Med Chem. 2017 Jul 13;60(13):5857-5867. doi: 10.1021/acs.jmedchem.7b00293. Epub 2017 Jun 23.
7
Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
J Thorac Dis. 2017 Mar;9(3):655-665. doi: 10.21037/jtd.2017.03.104.
8
In vivo IL-4 prevents allo-antigen driven CD8 CTL development.
Clin Immunol. 2017 Jul;180:11-24. doi: 10.1016/j.clim.2017.03.008. Epub 2017 Mar 27.
9
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Adv Exp Med Biol. 2017;995:73-95. doi: 10.1007/978-3-319-53156-4_4.
10
Mechanisms of Resistance to Immune Checkpoint Antibodies.
Handb Exp Pharmacol. 2018;249:109-128. doi: 10.1007/164_2017_11.
Zotero 插件